Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2005-10-11
2005-10-11
Canella, Karen A. (Department: 1642)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093710
Reexamination Certificate
active
06953573
ABSTRACT:
Compounds and compositions for eliciting or enhancing immune reactivity to HER-2
eu protein are disclosed. The compounds include polypeptides and nucleic acid molecules encoding such peptides. The compounds may be used for the prevention or treatment of malignancies in which the HER-2
eu oncogene is associated.
REFERENCES:
patent: 3766162 (1973-10-01), Spector
patent: 3791932 (1974-02-01), Schuurs et al.
patent: 3817837 (1974-06-01), Rubenstein et al.
patent: 3850752 (1974-11-01), Schuurs et al.
patent: 3901654 (1975-08-01), Gross
patent: 3935074 (1976-01-01), Rubenstein et al.
patent: 3984533 (1976-10-01), Uzgiris
patent: 3996345 (1976-12-01), Ullman et al.
patent: 4034074 (1977-07-01), Miles
patent: 4098876 (1978-07-01), Piasio et al.
patent: 4233402 (1980-11-01), Maggio et al.
patent: 4452901 (1984-06-01), Gordon et al.
patent: 5320947 (1994-06-01), Cheever et al.
patent: 5401638 (1995-03-01), Carney et al.
patent: 5693522 (1997-12-01), Chada et al.
patent: WO 90/14357 (1990-11-01), None
patent: WO 91/02062 (1991-02-01), None
“Gene therapy”, www.gateway.nlm.nih.gov, visited Jan. 23, 2004.
Verma et al (Nature, 1997, vol. 389, pp. 239-242).
Eck et al (Gene-Based Therapy, In: The Pharmacological Basis of Therapeutics, Goodman and Gilman, Ed.s, 1996, pp. 77-101).
Orkin et al state ( “Report and Recommendation of the Panel to Assess the NIH Investment in Research on Gene Therapy”, NIH, 1995).
Davis et al, “Plasmid DNA is superior to viral vectors for direct gene transfer into adult mouse skeletal muscle”, Hum Gene Ther, vol. 4, pp. 733-740, Dec. 1993.
Wickham, T.J., “Targeting Adenovirus”, Gene therapy, vol. 7, pp. 110-114, Jan. 2000.
Crystal, R.G., “In vivo and ex vivo gene therapy strategies to treat tumors using adenovirus gene transfer vectors”, Cancer chemotherapy and Pharmacology, vol. 43, Suppl., pp. S90-S99, May 1999.
Yamamoto et al., “Similarity of protein encoded by the c-erb-B-2 gene to epidermal growth factor receptor,”Nature 319: 230-234, 1986.
Zabrecky et al., “The Extracellular Domain of p185
eu Is Released from the Surface of Human Breast Carcinoma Cells, SK-BR-3,”Journal of Biological Chemistry 266(3): 1716-1720, 1991.
Press et al., “Expression of the HER-2
eu proto-oncogene in normal human adult and fetal tissues,”Oncogene 5: 953-962, 1990.
Raines and Ross, “Platelet-derived Growth Factor. I. High Yields Purification and Evidence for Multiple Forms,”Journal of Biological Chemistry 257(9): 5154-5159, 1982.
Riberdy and Cresswell, “The Antigen-Processing Mutant T2 Suggests a Role for MHC-Linked Genes in Class II Antigen Presentation,”Journal of Immunology 148(8):2586-2590, 1992.
Rothbard and Taylor, “A sequence pattern common to T cell epitopes,”EMBO Journal 7(1): 93-100, 1988.
Semba et al., “A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma,”Proc. Natl. Acad. Sci. USA 82: 6497-6501, 1985.
Spies et al., “A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway,”Nature 348: 744-747, 1990.
Stern et al., “Oncogene Activation of p185(neu) Stimulates Tyrosine Phosphorylation In Vivo,” Molecular and Cellular Biology 8(9): 3969-3973, 1988.
Trowsdale et al., “Sequence encoded in the class II region of the MHC related to the ‘ABC’ superfamily of transporters,” Nature 348: 741-744, 1990.
Weiner et al., “A point mutation in the neu oncogene mimics ligand induction of receptor aggregation,”Nature 339: 230-231, 1989.
Wide, L., “Solid Phase Antigen-Antibody Systems,” in Radioimmunoassay Methods, Kirkham and Hunter (ed.), 1973, pp. 405-412.
Wisdom, G.B., “Enzyme-Immunoassay,”Clin. Chem. 22(8): 1243-1255, 1976.
Leitzel et al., “Elevated Soluble c-erbB2 Antigen Levels in the Serum and Effusions of a Proportion of Breast Cancer Patients,”Journal of Clinical Oncology 10(9): 1436-1443, 1992.
Lichtenstein et al., “Effects of .beta.-2 Microglobulin Anti-sense oligonucleotides on Sensitivity of HER2
eu Oncogene-Expressing and Nonexpressing Target Cells to Lymphocyte-Mediated Lysis,”Cellular Immunology 141: 219-232, 1992.
Lippman, M., “Potential Contributions of Breast Cancer Biology to Management of Breast Cancer,”Advances in Oncology 8(3): 26-28, 1992.
Maguire and Greene, “The neu (c-erbB-2) Oncogene,”Seminars in Oncology 16(2): 148-155, 1989.
Margalit et al., “Prediction Of Immunodominant Helper T Cell Antigenic Sites From The Primary Sequence,”Journal of Immunology 138(7): 2213-2229, 1987.
McGlynn et al., “Large-scale purification and characterisation of a recombinant epidermal growth-factor receptor protein-tyrosine kinase. Modulation of activity by multiple factors,”Eur. J. Biochem. 207: 265-275, 1992.
McKenzie et al., “Induction of Antitumor Immunity by Immunization with a Vaccinia Virus Vector Expressing and Oncogene-encoded Product,” in Vaccines 88, Cold Spring Harbor Laboratory, 1988, pp. 19-23.
Mietzner et al., “Purification and Characterization of the Major Iron-Regulated Protein Expressed By Pathogenic Neisseriae,”Journal of Experimental Medicine 165: 1041-1057, 1987.
Mori et al., “In Vitro and in vivo Release of Soluble erbB-2 Protein from Human Carcinoma Cells,”Japanese Journal of Cancer Research 81: 489-494, 1900.
Paik et al., “Pathologic Findings From the National Surgical Adjuvant Breast and Bowel Project: Prognostic Significance of erbB-2 Protein Overexpression in Primary Breast Cancer,”Journal of Clinical Oncology8(1): 103-112, 1990.
Parker et al., “Sequence Motifs Important For Peptide Binding To The Human MHC Class I Molecule, HLA-A2,”Journal of Immunology 149(11): 3580-3587, 1992.
Flanagan and Leder, “neu protoncogene fused to an immunoglobulin heavy chain gene requires immunoglobulin light chain for cell surface expression and oncogenic transformation,”Proc. Natl. Acad. Sci. USA 85: 8057-8061, 1998.
Igelhart et al., “Increased erbB-2 Gene Copies and Expression in Multiple States of Breast Cancer,”Cancer Research 50: 6701-6707, 1990.
Ioannides et al., “Antigens Recognized by T cells in Ovarian Cancer,” in Abstracts of the Fourth International Conference of Anticancer Research, Oct. 21-25, 1992, Rethymnon, Crete, Greece, p. 1870.
Ioannides et al., “CTL Clones Isolated from Ovarian Tumor Infiltrating Lymphocytes can Recognize Peptides with Sequence Corresponding to the HER2
eu Gene Product,”FASEB Journal 6: A1404, Abstract No. 2711, 1992.
Ioannides et al., “Cytotoxic T Cells Isolated From Ovarian Malignant Ascites Recognize a Peptide Derived From the HER-2
eu Proto-oncogene,”Cell. Immunol. 151: 225-234, 1993.
Ioannides et al., “Cytotoxic T-Cell Clones Isolated from Ovarian Tumour Infiltrating Lymphocytes Recognize Common Determinants on Non-Ovarian Tumour Clones,”Scand. J. Immunol. 37: 413-424, 1993.
Ioannides et al., “T-Cell Recognition of Oncogene Products: A New Strategy for Immunotherapy,”Molecular Carcinogenesis 6: 77-82, 1992.
Ioannides, “Antigens and vaccines of female genital cancers (Meeting abstract),” Cancerlit Database Abstract No. ICDB/93690682, 1992.
Kallioniemi et al., “ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization,”Proc. Natl. Acad. Sci. 89: 5321-5325, 1992.
Kerns et al., “c-erbB-2 Expression In Breast Cancer Detected by Immunoblotting and Immunohistochemistry,”Journal of Histochemistry and Cytochemistry 38(12): 1823-1830, 1990.
Laemmli, U., “Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4,”Nature 227: 680-685, 1970.
Bodmer, W.,
Cheever Martin A.
Disis Mary L.
Canella Karen A.
Seed IP Law Group PLLC
University of Washington
LandOfFree
Compounds for eliciting or enhancing immune reactivity to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds for eliciting or enhancing immune reactivity to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for eliciting or enhancing immune reactivity to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3447308